WO2007120651A3 - Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile - Google Patents

Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile Download PDF

Info

Publication number
WO2007120651A3
WO2007120651A3 PCT/US2007/008826 US2007008826W WO2007120651A3 WO 2007120651 A3 WO2007120651 A3 WO 2007120651A3 US 2007008826 W US2007008826 W US 2007008826W WO 2007120651 A3 WO2007120651 A3 WO 2007120651A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
jra
rheumatoid arthritis
juvenile rheumatoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/008826
Other languages
English (en)
Other versions
WO2007120651A2 (fr
Inventor
John R Medich
Nicolino Ruperto
Alberto Martini
Daniel J Lovell
Edward H Giannini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
Abbott Biotech Ltd Bermuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotech Ltd Bermuda filed Critical Abbott Biotech Ltd Bermuda
Priority to EP07755184A priority Critical patent/EP2010213A4/fr
Publication of WO2007120651A2 publication Critical patent/WO2007120651A2/fr
Publication of WO2007120651A3 publication Critical patent/WO2007120651A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes, des utilisations et des compositions pour le traitement de l'arthrite rhumatoïde juvénile (ARJ). L'invention décrit des méthodes et des utilisations pour le traitement de l'ARJ, dans lesquelles un inhibiteur de TNFα, tel qu'un anticorps TNFα humain, ou une partie de celui-ci se liant à l'antigène, est utilisé pour prévenir les poussées actives associées à l'ARJ. L'invention concerne également des méthodes permettant de déterminer l'efficacité d'un inhibiteur de TNFα pour le traitement de l'ARJ chez un sujet.
PCT/US2007/008826 2006-04-10 2007-04-10 Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile Ceased WO2007120651A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07755184A EP2010213A4 (fr) 2006-04-10 2007-04-10 Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US79090906P 2006-04-10 2006-04-10
US60/790,909 2006-04-10
US80977006P 2006-05-30 2006-05-30
US60/809,770 2006-05-30
US81548906P 2006-06-20 2006-06-20
US60/815,489 2006-06-20
US85837606P 2006-11-10 2006-11-10
US60/858,376 2006-11-10

Publications (2)

Publication Number Publication Date
WO2007120651A2 WO2007120651A2 (fr) 2007-10-25
WO2007120651A3 true WO2007120651A3 (fr) 2008-07-31

Family

ID=38610129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/008826 Ceased WO2007120651A2 (fr) 2006-04-10 2007-04-10 Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile

Country Status (2)

Country Link
EP (1) EP2010213A4 (fr)
WO (1) WO2007120651A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
EP3002299A1 (fr) * 2008-06-03 2016-04-06 AbbVie Inc. Immunoglobulines à deux domaines variables et leurs utilisations
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
EP2970459A2 (fr) 2013-03-15 2016-01-20 AbbVie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1beta et il -17
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US20030235585A1 (en) * 2001-06-08 2003-12-25 Fischkoff Steven A. Methods of administering anti-TNFalpha antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US20030235585A1 (en) * 2001-06-08 2003-12-25 Fischkoff Steven A. Methods of administering anti-TNFalpha antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2010213A4 *

Also Published As

Publication number Publication date
WO2007120651A2 (fr) 2007-10-25
EP2010213A4 (fr) 2010-08-11
EP2010213A2 (fr) 2009-01-07

Similar Documents

Publication Publication Date Title
WO2008063213A3 (fr) Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
WO2007120656A3 (fr) Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
WO2008154543A3 (fr) Procédés de traitement de l'arthrite idiopathique juvénile
WO2006003388A3 (fr) Compositions et procedes pour le traitement de troubles inflammatoires
WO2005105780A3 (fr) Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
WO2009109908A8 (fr) Procédés de traitement d'une douleur inflammatoire
WO2005103050A3 (fr) Azaindoles utiles en tant qu'inhibiteurs de la proteine serine/threonine kinase superhelice de la famille rho (rock) et d'autres proteines kinases
WO2006083971A3 (fr) Anticorps dr5 et utilisations de ceux-ci
WO2007058942A3 (fr) Imidazopyrazines inhibant la proteine kinase
WO2007090569A8 (fr) Composition sanguine conditionnée et son procédé de préparation
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2007076423A3 (fr) INHIBITEURS D’ACTIVITE Akt
WO2006102504A3 (fr) Combinaisons destinees au traitement de cancer
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
WO2005097825A3 (fr) Variants de bmp-7 ayant des proprietes ameliorees
EP2030615A3 (fr) Inhibiteurs de la ribonucleotide reductase pour leur utilisation dans le traitement ou la prévention de maladies neuro-inflammatoires ou auto-immunes
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
WO2006015258A3 (fr) Procedes et compositions associes aux proteines argonautes
WO2009009034A3 (fr) Procédées et compositions utiles dans le traitement de la mucosite
WO2007120720A3 (fr) Utilisations et compositions pour le traitement de la maladie de crohn
WO2005117979A3 (fr) Utilisation de il-17 pour traiter les troubles de la fertilite
WO2006028524A3 (fr) Compositions et traitements pour l'inhibition de kinase et/ou de hmg-coa reductase
EP2666479A3 (fr) Utilisations et compositions pour le traitement de l'arthrite rhumatoïde juvénile

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755184

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007755184

Country of ref document: EP